



PRESS TOUR

HEALTHS & BIOTECHS

Preliminary Programme

11 July 2018

PRESS TOUR PROGRAMME

From bench to bed: the Toulouse's approach in oncology A recent story on melanoma

**Wednesday 11 July, 13h – 16h45
Toulouse Oncopole**

This Health Press Tour gives you the opportunity to visit the Cancer Research Center of Toulouse (CRCT) closely associated with the “ Institut universitaire du cancer de Toulouse – Oncopole “ IUCT-Oncopole which includes a Cancer Center (Institut Claudius Regaud) and many teams from the Toulouse University Hospital. A presentation of a recent study on melanoma published in *Nature Communications* will illustrate the continuum, between research and care (from basic research to bedside and vice-versa). Cancer Bio Santé Cluster will explain the development of spin-offs based on the results of academic research.

The CRCT and IUCT-Oncopole are located on the Oncopole, in the Campus of Langlade, in Toulouse. For the first time in Europe, public and private laboratories, hospital, university, cancer centers, companies and associations joined their forces to fight against cancer.

Program

13h – 14h: Welcome lunch

14h – 14h30: Introduction by Gilles Favre (CRCT), Armelle Barelli (Inserm), Jean-Pierre Vinel (Toulouse III – Paul Sabatier University), Anne Ferrer (CHU) and Alexis Monnier (Cancer-Bio-Santé Cluster)

14h30 – 15h15: Visit of the CRCT's and the IUCT-Oncopole's infrastructures

15h15 – 16h15: Presentations of recent research on melanoma and discussions

16h15 – 16h45: Informal discussions and face-to-face interview

16h45: Departure

Speakers

Gilles Favre – Director of the Cancer Research Center of Toulouse

Armelle Barelli – Regional representative of Inserm


Jean-Pierre Vinel – President of Toulouse III – Paul Sabatier University

Anne Ferrer – Deputy Director of Toulouse University Hospital
Alexis Monnier – Director of the Cancer-Bio-Santé Cluster
Frédéric Lopez – Head of the technological facilities of the CRCT
Bruno Ségui – University professor / researcher at Toulouse III – Paul Sabatier University and CRCT
Nicolas Meyer – Oncodermatologist, Professor at CHU de Toulouse
Anne Montfort – Post-doctoral fellow at CRCT
Romain Vié, Technical Sales engineer at Pixience Company

Anti-TNF α potentiate melanoma immunotherapy

Metastatic melanoma is a poor-prognosis skin cancer. Immunotherapy, based on the use of monoclonal antibodies (anti-CTLA-4 and anti-PD-1), activates the immune system to fight melanoma and has dramatically improved the prognosis of this cancer. Those antibodies block checkpoints, which act as brakes to prevent the attack of cancer cells by T lymphocytes. However, a significant proportion of patients does not respond to such immunotherapies and/or develops severe side effects, some of which can be treated by potent anti-inflammatory drugs, such as the anti-TNF α .

In this context, a preclinical study carried out by researchers from the Cancer Research Center of Toulouse under the supervision of Prof. Bruno Ségui, shows that blockade of TNF or its receptor, TNFR1, enhances the response to anti-PD-1 in melanoma, lung and breast cancer models. TNF was also shown to modulate a family of lipids called sphingolipids, whose metabolism has been shown to be dysregulated in melanoma. Ongoing research supported by Europe (ERA-NET Transcan2: Immusphinx; PI: Dr. Nathalie Andrieu-Abadie) aims at evaluating how targeting the sphingolipid metabolism can overcome resistance to immunotherapy.



These works, based on tight collaborations with the departments of Pathology and Biostatistics of IUCT-Oncopole, led to a publication in Nature Communications, one international patent and two clinical trials (TICIMEL et MELANF α) in advanced melanoma patients at the IUCT-Oncopole in 2018 (PI Prof. Nicolas Meyer, IUCT and CHU Toulouse) as well as collaborations with European leaders in the field of melanoma pathophysiology and genetics.

Bibliography

TNF α blockade overcomes resistance to anti-PD-1 in experimental melanoma

Florie Bertrand, Anne Montfort, Elie Marcheteau, Caroline Imbert, Julia Gilhodes, Thomas Filleron, Philippe Rochaix, Nathalie Andrieu-Abadie, Thierry Levade, Nicolas Meyer, Céline Colacios and Bruno Ségui, *Nat. Commun.* 2017 Dec 22;8(1):2256. doi: 10.1038/s41467-017-02358-7.

The Cancer Research Center of Toulouse

The Cancer Research Center of Toulouse is a joint research unit (UMR 1037) institutionally recognized by the French National Institute of Health and Medical Research (Inserm) and the Toulouse III - Paul Sabatier University. Some teams are also labeled by the CNRS.

At the heart of the Oncopole of Toulouse, the CRCT, together with all its partners (institutional, academic, clinical, industrial, charities...), stimulates innovation in cancer research by leading an integrated approach between research, care and training, with a transversal and multidisciplinary vision. The basic research is coordinated through 4 lines:

- Oncogenic signaling, DNA damage response & genetic instability.
- RNA and cancer.
- Tumor microenvironment and metabolism.
- Onco-Immunology.

Learn more: www.crct-inserm.fr

Learn more: www.inserm.fr

Learn more: www.univ-tlse3.fr

The IUCT-Oncopole

The IUCT Oncopole comprises the Institut Claudius Regaud, a comprehensive Cancer Center, and several teams from Toulouse University Hospital. The two institutions offer the expertise of 1 500 professionals specialized in oncology on the same site. The Institute is located in the heart of a campus gathering public and private stakeholders involved in the fight against cancer, with three interdependent missions: care, research and training.

Learn more: www.iuct-oncopole.fr

Learn more: www.chu-toulouse.fr

Cancer-Bio-Santé Cluster

A mission for innovation and competitiveness

The Cancer-Bio-Santé Cluster is the only French cluster wholly dedicated to innovation in the field of cancer and healthy ageing, from biotechnology to medical devices.

The cluster was created to provide support for more than 200 companies in Occitanie Region, working together with research laboratories, cancer centers and hospitals, university, to develop innovative products in cancer and healthy ageing, from prevention to follow up and home care including e-health technologies.

Learn more: www.cancerbiosante.fr

Pixience Company

Specialists in imaging devices and measurement for skin exploration.

Our work involves making scientific and professional techniques available for the exploration and characterisation of living organisms. From a single cell to the entire body, our expertise forms a link between physics and skin physiology. This experience allows us to design, manufacture and market innovative analysis methods and systems. Within this framework, our aim is to provide new solutions to counter issues faced by the various stakeholders in the fields of healthcare, biology, dermatology and dermocosmetics. Our trademark is our ongoing effort to shake up a technologically-stagnant domain subjected to a quasi-monopoly, and to provide innovative ideas and solutions to address the challenges of the future.

Based near Toulouse's Oncopole, each year we invest in research and development with our a team of researchers specialised in the fields of physics and engineering. “

Learn more: www.pixience.com



PRESS CONTACTS

INSERM Toulouse Contact

Christine Ferran
christine.ferran@inserm.fr

ESOF 2018 Press Contact



ESOF 2018 Press Contact

Alexandra Foissac, PhD
Communication & Press Relations ESOF Toulouse 2018

alexandra.foissac@toulouse2018.esof.eu
+33 (0)5 61 009119



ORGANISERS AND PARTNERS

